|
Tracking plasma KRAS mutations (mu) in lung adenocarcinoma (LUAC) patients (p) and branching evolution. |
|
|
Employment - Pangaea Oncology |
|
|
No Relationships to Disclose |
|
|
Employment - Guardant Health; Veracyte |
Leadership - Biolase; Guardant Health |
Stock and Other Ownership Interests - Biolase; Forward; Guardant Health |
Speakers' Bureau - Forward |
Research Funding - Guardant Health |
|
|
Stock and Other Ownership Interests - Guardant Health |
|
|
No Relationships to Disclose |
|
|
Employment - Guardant Health |
Stock and Other Ownership Interests - Guardant Health |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Roche |
Speakers' Bureau - Bristol-Myers Squibb; Roche |
Research Funding - Merck Serono (Inst); Roche (Inst); SERVIER (Inst) |
Travel, Accommodations, Expenses - Roche; SERVIER |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Guardant Health; Lilly; Merck Sharp & Dome; Novartis; Pfizer |
Speakers' Bureau - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Guardant Health; Lilly; Merck Sharp & Dome; Novartis; Pfizer; Roche; Takeda |
Research Funding - Merck Serono (Inst) |
|
|
No Relationships to Disclose |